Stoke Therapeutics, Inc. Common Stock
STOK
STOK: Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.
moreShow STOK Financials
Recent trades by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by STOK's directors and management
Government lobbying spending instances
-
$30,000 Jan 19, 2023 Issue: Health Issues
-
$30,000 Oct 20, 2022 Issue: Health Issues
-
$30,000 Jul 19, 2022 Issue: Health Issues
-
$30,000 Apr 19, 2022 Issue: Health Issues
New patents grants
-
Patent Title: Antisense oligomers and uses thereof Aug. 24, 2021
-
Patent Title: Antisense oligomers for treatment of conditions and diseases Feb. 09, 2021
-
Patent Title: Antisense oligomers for treatment of conditions and diseases Jun. 16, 2020
Federal grants, loans, and purchases
Followers on company's Twitter account
Number of mentions of STOK in WallStreetBets Daily Discussion
Recent insights relating to STOK
Recent picks made for STOK on CNBC
ETFs with the largest estimated holdings in STOK
Flights by private jets registered to STOK